Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer

BACKGROUND: Systemic failure remains a challenge in rectal cancer. We investigated the possible systemic anti-tumour immune activity invoked within oxaliplatin-based neoadjuvant therapy. METHODS: In two high-risk patient cohorts, we assessed the circulating levels of the fms-like tyrosine kinase 3 l...

Descripción completa

Detalles Bibliográficos
Autores principales: Kalanxhi, Erta, Meltzer, Sebastian, Schou, Jakob Vasehus, Larsen, Finn Ole, Dueland, Svein, Flatmark, Kjersti, Jensen, Benny Vittrup, Hole, Knut Håkon, Seierstad, Therese, Redalen, Kathrine Røe, Nielsen, Dorte Lisbet, Ree, Anne Hansen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5959927/
https://www.ncbi.nlm.nih.gov/pubmed/29695770
http://dx.doi.org/10.1038/s41416-018-0085-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5959927/
https://www.ncbi.nlm.nih.gov/pubmed/29695770
http://dx.doi.org/10.1038/s41416-018-0085-y

Ejemplares similares